Cohance Lifesciences Q1 FY27 Results: Revenue Down 23.1% YoY to ₹422.3 Crore; AGM on Sep 17
Cohance Lifesciences reported Q1 FY27 consolidated revenue of ₹422.3 crore, down 23.1% YoY. Adjusted EBITDA was ₹9.2 crore. The company approved reorganization at subsidiary Sapala Organics and will hold its 8th AGM on September 17, 2026. Management expects Q2 improvement and H2 growth.
The financial results show a decline, but the company has a positive outlook for the second half of the fiscal year and is undertaking strategic initiatives which could mitigate the current negative impact.
The revenue and profit for the quarter have declined significantly year-on-year, indicating a negative financial performance.
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced its unaudited financial results for the first quarter ended June 30, 2026. The company reported consolidated revenue from operations of ₹422.3 crore (₹4,223 million), a decrease of 23.1% year-on-year. Gross margins contracted to 71.5% from 73.0% in Q1 FY26, attributed to product mix and lower contribution from the CDMO business. Adjusted EBITDA stood at ₹9.2 crore (₹92 million), with margins at 2.2%, reflecting the lower revenue base, negative operating leverage, and the impact of subsidiary consolidation.
The standalone business generated revenue of ₹359.9 crore (₹3,599 million) and adjusted EBITDA of ₹33.2 crore (₹332 million), representing a margin of 9.2%. Sapala contributed revenue of approximately ₹27.4 crore, while NJ Bio reported revenue of ₹35 crore and an adjusted EBITDA loss.
Capital expenditure during the quarter was approximately ₹59.8 crore. Consolidated net cash stood at approximately ₹251.2 crore as of June 30, 2026. The company's Board of Directors also approved the reorganization at Sapala Organics Private Limited, a subsidiary, and the convening of the 8th Annual General Meeting (AGM) on Thursday, September 17, 2026.
Mr. Umang Vohra, Executive Chairman and Group CEO, stated that Q1 was expected to be the lowest quarter and anticipates improvement in Q2, with a return to year-on-year growth from the second half, supported by secured orders and pipeline progress. The company is focusing on integrating its nucleic-acid business with Sapala and repositioning Agrochemicals.
What to do with a filing like this
Cohance Lifesciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Cohance Lifesciences Limited. Read the original for the full detail.